Pfizer reports pediatric vaccine data: what it means for Pfizer stock
Published on 10/25/2026 at 17:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPediatric vaccine data and timing
- On October 24, 2026, Pfizer reported Phase 2 findings for its 25-valent pediatric pneumococcal vaccine candidate.
- Pfizer stock trades in weekend trading at Lang & Schwarz at EUR 26.82 at 5:21 p.m. CEST on October 25, 2026.
- The next Xetra session is scheduled for October 26, 2026.
Pfizer reported detailed Phase 2 findings for its investigational 25-valent pneumococcal conjugate vaccine candidate in infants on October 24, 2026, according to AP News. The company said the four-dose series produced immune responses against all 25 serotypes and showed safety and tolerability comparable to four doses of PREVNAR 20.
In weekend trading at Lang & Schwarz, Pfizer stock was EUR 26.82 at 5:21 p.m. CEST on October 25, 2026.
Market context: Market report S&P 500.
Pfizer vaccine findings
Pfizer said the study findings were presented at IDWeek 2026 in Washington, D.C. The company also said the results support an ongoing Phase 3 development program for the candidate. The investigational vaccine targets five additional serotypes beyond PREVNAR 20, according to the release.
Next Xetra session
The next Xetra session is scheduled for October 26, 2026. No forecast is implied by that calendar date.
The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CEST is shown by the continuously updated real-time quote of Pfizer stock.
